Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Guardian Pharmacy Services Inc (NYSE: GRDN) was $25.43 for the day, down -3.75% from the previous closing price of $26.42. In other words, the price has decreased by -$3.75 from its previous closing price. On the day, 1.59 million shares were traded. GRDN stock price reached its highest trading level at $26.7 during the session, while it also had its lowest trading level at $25.34.
Ratios:
Our analysis of GRDN’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 85.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 42.45. For the most recent quarter (mrq), Quick Ratio is recorded 0.88 and its Current Ratio is at 1.18. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.16.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Truist on October 21, 2024, initiated with a Buy rating and assigned the stock a target price of $22.
On October 21, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $21.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 27 ’25 when BINDLEY WILLIAM E sold 3,508,905 shares for $20.16 per share. The transaction valued at 70,739,525 led to the insider holds 2,591,271 shares of the business.
BINDLEY WILLIAM E sold 651,454 shares of GRDN for $13,133,313 on May 28 ’25. The Director now owns 1,939,817 shares after completing the transaction at $20.16 per share. On May 27 ’25, another insider, Salentine Thomas J Jr, who serves as the Director of the company, sold 3,508,905 shares for $20.16 each. As a result, the insider received 70,739,525 and left with 2,591,271 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GRDN now has a Market Capitalization of 1610257152 and an Enterprise Value of 1641402112. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.21 while its Price-to-Book (P/B) ratio in mrq is 9.49. Its current Enterprise Value per Revenue stands at 1.237 whereas that against EBITDA is -44.523.
Stock Price History:
The Beta on a monthly basis for GRDN is 1.02, which has changed by 0.589375 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, GRDN has reached a high of $30.39, while it has fallen to a 52-week low of $14.16. The 50-Day Moving Average of the stock is 6.14%, while the 200-Day Moving Average is calculated to be 14.05%.
Shares Statistics:
GRDN traded an average of 264.68K shares per day over the past three months and 503420 shares per day over the past ten days. A total of 22.73M shares are outstanding, with a floating share count of 19.30M. Insiders hold about 69.51% of the company’s shares, while institutions hold 29.05% stake in the company. Shares short for GRDN as of 1756425600 were 339162 with a Short Ratio of 1.28, compared to 1753920000 on 515096. Therefore, it implies a Short% of Shares Outstanding of 339162 and a Short% of Float of 2.69.
Earnings Estimates
A comprehensive evaluation of Guardian Pharmacy Services Inc (GRDN) is underway, with the input of 3.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.25, with high estimates of $0.26 and low estimates of $0.25.
Analysts are recommending an EPS of between $0.98 and $0.94 for the fiscal current year, implying an average EPS of $0.97. EPS for the following year is $1.04, with 3.0 analysts recommending between $1.1 and $1.0.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 3 analysts. It ranges from a high estimate of $359.16M to a low estimate of $352.2M. As of. The current estimate, Guardian Pharmacy Services Inc’s year-ago sales were $314.39MFor the next quarter, 3 analysts are estimating revenue of $371.68M. There is a high estimate of $372.2M for the next quarter, whereas the lowest estimate is $370.73M.
A total of 3 analysts have provided revenue estimates for GRDN’s current fiscal year. The highest revenue estimate was $1.4B, while the lowest revenue estimate was $1.4B, resulting in an average revenue estimate of $1.4B. In the same quarter a year ago, actual revenue was $1.23BBased on 3 analysts’ estimates, the company’s revenue will be $1.43B in the next fiscal year. The high estimate is $1.43B and the low estimate is $1.43B.
